Friday, 16 October 2026European Markets

WERELDHAVE BELGIUM And COURTOIS Have A High Dividend Yield And Return On Equity In The Real Estate Sector.

Loading stream...

(vianews) - wereldhave belgium (wehb.br) is among this list of stock assets with the highest dividend rate and return on equity on the real estate sector.

financial asset price forward dividend yield return on equity
wereldhave belgium (wehb.br) €44.00 9.77% 5.61%
courtois (cour.pa) €128.00 2.18% 3.22%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. wereldhave belgium (wehb.br)

9.77% forward dividend yield and 5.61% return on equity

wereldhave belgium is a public regulated real estate company with a focus on commercial property in belgium. wereldhave belgium targets its new investments on shopping centres. the value of the real estate portfolio, including project developments, amounted to € 921.2 mln on 31 december 2020. on 31 december 2020 the existing operational retail portfolio amounted to € 817.8 mln (around 90% of the total portfolio) and it includes shopping centres in liège, nivelles, tournai, genk and kortrijk and retail parks in brugge, ghent, turnhout, waterloo and tournai. in addition, the portfolio of real estate investments includes offices in vilvoorde and antwerp. as of 31 december 2020 the development portfolio of € 12.6 mln contained land holdings and realised investments that relate to the refurbishment and/or expansion of shopping centres in waterloo and liège.

earnings per share

as for profitability, wereldhave belgium has a trailing twelve months eps of €4.28.

pe ratio

wereldhave belgium has a trailing twelve months price to earnings ratio of 10.28. meaning, the purchaser of the share is investing €10.28 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.61%.

revenue growth

year-on-year quarterly revenue growth grew by 10.8%, now sitting on 63.4m for the twelve trailing months.

volume

today's last reported volume for wereldhave belgium is 59 which is 94.34% below its average volume of 1043.

dividend yield

as maintained by morningstar, inc., the next dividend payment is on apr 17, 2023, the estimated forward annual dividend rate is 4.2 and the estimated forward annual dividend yield is 9.77%.

more news about wereldhave belgium.

2. courtois (cour.pa)

2.18% forward dividend yield and 3.22% return on equity

courtois s.a. renovates and sells real estate properties located in the midi-pyrenees and paris regions in france. courtois s.a. is based in toulouse, france.

earnings per share

as for profitability, courtois has a trailing twelve months eps of €9.29.

pe ratio

courtois has a trailing twelve months price to earnings ratio of 13.78. meaning, the purchaser of the share is investing €13.78 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.22%.

volume

today's last reported volume for courtois is 15 which is 67.39% below its average volume of 46.

yearly top and bottom value

courtois's stock is valued at €128.00 at 01:30 est, under its 52-week high of €138.00 and above its 52-week low of €119.00.

dividend yield

as maintained by morningstar, inc., the next dividend payment is on may 30, 2023, the estimated forward annual dividend rate is 2.75 and the estimated forward annual dividend yield is 2.18%.

revenue growth

year-on-year quarterly revenue growth declined by 76.2%, now sitting on 9.07m for the twelve trailing months.

more news about courtois.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com